FIND and QIAGEN improve collaboration for novel TB tests
The collaboration includes three areas of TB testing, including a test that will detect drug resistance at the point of care, tests that allow targeted preventive therapy, and sequencing as the future highest standard for TB regimen selection and surveillance.
“QIAGEN is the leading global provider of diagnostics for the detection of latent TB infections,” FIND Chief Executive Officer Catharina Boehme said. “We are pleased to intensify our partnership in the fight against TB as a first step and hope to expand to other disease areas going forward.”
The two companies will collaborate in order to develop these more accurate and more efficient tests, which should help to detect patients who have latent TB and a greater risk of developing active TB.
“We are very proud to partner with FIND in the worldwide fight against tuberculosis and to develop together innovative and affordable diagnostics ranging from latent TB detection to tests for drug resistance mechanism,” Thierry Bernard, senior vice president of the Molecular Diagnostics Business Area and member of the executive committee of QIAGEN, said.